Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and relaxing, because that predictable routine of meetings, deadlines, and what-not has, of course, returned. As always, we are coping with a few cups of stimulation, but also fortified by a delightful combination of a cool breeze and warm sun. In any event, this is an adjustment process. Meanwhile, here are a few items of interest to help you. We hope your day is productive and do keep us in mind when something fascinating arises …
Multinational drug makers in China are fighting to hold on to top talent as senior local staff leave to join a booming domestic biotechnology sector drawing record investment, The Financial Times tells us. They are joining a sector that received a record $11.7 billion of venture capital investment in 2017, more than double the $5.3 billion invested in 2016, with about $2.6 billion going to drug developers. In addition, Chinese drug companies raised more than $3.1 billion from equity markets last year, and billions more from licensing agreements.
Indivior vowed to pursue all legal options and seek an immediate injunction against a Food and Drug Administration decision last week to approve the first copycat versions of its best-selling Suboxone opioid addiction treatment, Reuters says. Last Thursday, Dr Reddy’s Laboratories (RDY) and Mylan (MYL) won FDA approval for a generic version of Suboxone Film, which generates 80 percent of Indivior revenue. Generic tablets are already available in the U.S. market, but Suboxone Film leads the market with its version, which is placed under the tongue to suppress cravings.
About the Author Reprints
